TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00002766

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dactinomycin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sargramostim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carmustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegaspargase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03240965

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological testing
Description: Neuropsychological testing for neglect, agnosia
Study: NCT04245852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength education video
Description: The Strength education video must be watched by the patient at the University of Illinois at Chicago Faculty Practice (UICFP) prior to leaving from the 3rd physical therapy visit. The Experimental Group (EG) will watch the video in the waiting room or other quiet available rooms on the 3rd floor within the UICFP. The video will be watched from an iPad/tablet/laptop/desktop computer device as available in the clinic. The EG will also be provided a handout with a link and quick response code to the video on YouTube.com

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard PT care
Description: standard PT care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard PT care
Description: standard PT care
Study: NCT04177667

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Proxeed
Description: Treatment with dietary supplement for male infertility for Proxeed Arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo for Placebo Arm
Study: NCT04524897

Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone Injection in treatment of refractory benign Esophageal Stricture in children
Description: Triamcinolone Injection in treatment of refractory benign Esophageal Stricture with endoscopic dilatation
Study: NCT01270516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMB, hydroxymethylbutyrate
Description: Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMB, hydroxymethylbutyrate
Description: Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA, eicosapentaenoic acid
Description: EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days
Study: NCT03190122

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical excision of the tumor
Description: Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. \[NCT ID not yet assigned\]

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical excision of the tumor
Description: Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. \[NCT ID not yet assigned\]
Study: NCT01270516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA, eicosapentaenoic acid
Description: EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Control
Study: NCT03041077

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Instaflex Advanced
Description: Joint function

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01191333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Repetitive Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Device
Description: Placebo Device that simulates active rTMS treatment
Study: NCT03373435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exendin 9-39
Description: Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.
Study: NCT02587234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peripheral nerve stimulation
Description: Non-invasive stimulation of median, ulnar and radial nerves

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: peripheral nerve stimulation
Description: Non-invasive stimulation of median, ulnar and radial nerves
Study: NCT03792191

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lumbar Spinal Ultrasonography
Description: Ultrasonography of the lumbar spines using an 8-2 MHz curved array transducer. Identification of the intervertebral space with the best image. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Sham Ultrasound Procedure
Description: Moving the ultrasound probe on the patient's back with the machine in the freeze position.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Landmark Palpation
Description: Conventional palpation of the anatomical landmarks. The line crossing the iliac crests (Tuffier line) is assumed to cross the spine at L4 spinous process or L3-L4 intervertebral space. Identification of the widest intervertebral space. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Spinal anesthesia using a 25- or 22-gauge spinal needle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Spinal anesthesia using a 25- or 22-gauge spinal needle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Bupivacaine
Description: Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Bupivacaine
Description: Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Fentanyl
Description: Fentanyl 15 μg will be administered in the subarachnoid space

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Fentanyl
Description: Fentanyl 15 μg will be administered in the subarachnoid space
Study: NCT04394117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin Receptor Blockers
Description: Angiotensin Receptor Blockers (ARBs) have been in clinical use for more than 30 years for their cardiac and renal protective effects. ARBs mechanism of action is through selective inhibition of angiotensin-II (Ang-II) by competitive antagonism of the angiotensin receptor. ARBs displace ang-II from the angiotensin I receptor and produce their protective effects by reducing the downstream effects of ang-II induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic response The virus causing COVID-19, SARS-CoV-2, binds to the extracellular portion of Angiotensin-Converting-Enzyme-2 (ACE2) expressed on type II alveolar cells in the lungs which is followed by internalization of ACE2 before downregulating membrane ACE2 expression. Both these components appear to require angiotensin receptor Type 1 (AT1R), and ARBs, which block the actions of AT1R, would reduce the severity of COVID-19 and reduce the duration of symptoms

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03670888

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JHL1101
Description: 100 mg/10 mL solution in a single-use vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 100 mg/10 mL solution in a single-use vial
Study: NCT03373435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exendin 9-39
Description: Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.
Study: NCT02250417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wave sleep surface
Description: The Wave sleep surface is designed to be used as a bed surface and with any combinations of sleep pillows, bed linens, and bed clothes and intended to avoid the supine position during sleep.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wave sleep surface
Description: The Wave sleep surface is designed to be used as a bed surface and with any combinations of sleep pillows, bed linens, and bed clothes and intended to avoid the supine position during sleep.
Study: NCT03460860

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)
Description: The intervention is to be taken once daily, for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention is to be taken once daily, for 12 weeks.
Study: NCT02710396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2 (programmed cell death (PD) proteins).~Pembrolizumab 200 mg will be administered IV every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2 (programmed cell death (PD) proteins).~Pembrolizumab 200 mg will be administered IV every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2 (programmed cell death (PD) proteins).~Pembrolizumab 200 mg will be administered IV every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC (area under curve (AUC)) = 5 IV on day 1 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC (area under curve (AUC)) = 5 IV on day 1 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/m2 IV on days 1, 8 and 15 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
Study: NCT00000308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Description: 15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-amphetamine
Description: 15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study: NCT02980497

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listerine Zero Mouthwash (without alcohol)
Description: 20 ml of rinse for 30 seconds, twice a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listerine Antiseptic Mouthwash (with alcohol)
Description: 20 ml of rinse for 30 seconds, twice a day
Study: NCT02875054

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constraint induced movement therapy (CIMT)
Description: Involves forcing use of ones affected upper extremity (UE) by physically restraining the less affected upper extremity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constraint induced movement therapy (CIMT)
Description: Involves forcing use of ones affected upper extremity (UE) by physically restraining the less affected upper extremity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand-arm bimanual intensive training (HABIT)
Description: Facilitates the translation of gains to improve goal-directed bimanual performance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand-arm bimanual intensive training (HABIT)
Description: Facilitates the translation of gains to improve goal-directed bimanual performance.
Study: NCT02060123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong training
Description: a total of 103 hours over a period of 5.5 months, consisting of:~* Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),~* Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and~* Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours).

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list control- Health talks
Description: Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
Study: NCT02324257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6958688
Description: RO6958688 is given as an intravenous (IV) infusion as a single administration in Part I, and QW, Q3W, or as a combined QW/Q3W step up dosing regimen (cycle = 7 days in the QW regimen and cycle = 21 days in the Q3W regimen) in Part II of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6958688
Description: RO6958688 is given as an intravenous (IV) infusion as a single administration in Part I, and QW, Q3W, or as a combined QW/Q3W step up dosing regimen (cycle = 7 days in the QW regimen and cycle = 21 days in the Q3W regimen) in Part II of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is given as an IV infusion at a dose level of 2000 mg on Day -13 or 1000 mg on Days -13 and -12 prior to the treatment start with RO6958688 on Cycle 1 Day 1.
Study: NCT02773303

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mente Autism™
Description: A portable headband records EEG activity, and specialized algorithms convert the EEG activity into sonified binaural signals feeding them back to the user

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: a device externally identical to Mente Autism™, providing binaural beats but not tailor-made neurofeedback binaural beats
Study: NCT02324257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as an IV infusion as necessary to treat adverse events.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as an IV infusion as necessary to treat adverse events.
Study: NCT02151240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foscarnet Sodium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Study: NCT01194804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.
Study: NCT04229472

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High density electrophysiological mapping
Description: Recording of electrophysiological data using a high density contact catheter during pacing at the time of catheter ablation for atrial fibrillation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High density electrophysiological mapping
Description: Recording of electrophysiological data using a high density contact catheter during pacing at the time of catheter ablation for atrial fibrillation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High density electrophysiological mapping
Description: Recording of electrophysiological data using a high density contact catheter during pacing at the time of catheter ablation for atrial fibrillation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging
Description: Late gadolinium enhance cardiac magnetic resonance imaging (in AcQMap group only)
Study: NCT00151125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-11
Description: 25 mcg/kg subcutaneously daily for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-11
Description: 50 mcg/kg subcutaneously daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-11
Description: 10 mcg/kg subcutaneously daily for 7 days
Study: NCT02077985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Adapted Dental Environment
Description: See study arm description.
Study: NCT00479024

Intervention type: DRUG
Intervention: iodinated contrast agent
Description: iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
Study: NCT02969850

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D Supplementation
Description: Subjects in this group will receive initial dose of 2400, 3600, or 4800 IU of vitamin D3, based on her serum vitamin D level. Dose will be adjusted at 3 month visit to maintain serum vitamin D level at a desirable level.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this group will receive a placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: If dietary calcium intake is insufficient in participants of either group, they will be given a calcium supplement in the form of one 600mg pill of CaCO3 to bring them up to an intake of 1200mg/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: If dietary calcium intake is insufficient in participants of either group, they will be given a calcium supplement in the form of one 600mg pill of CaCO3 to bring them up to an intake of 1200mg/day.
Study: NCT01892319

Intervention type: DRUG
Intervention: insulin detemir
Description: Patients will be treated according to routine clinical practice at the discretion of the treating physician

Intervention type: DRUG
Intervention: other injectable antidiabetic treatment regimens
Description: Patients will be treated according to routine clinical practice at the discretion of the treating physician
Study: NCT01260363

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block
Description: Femoral nerve block ultrasound guidet with ropivacaine 20ml 2.5mg/ml
Study: NCT01528020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: DBT is a cognitive behavioral approach to treatment that synthesizes change based strategies characteristic of behavior therapy and validation strategies consistent with acceptance based treatments through application of dialectical principles and techniques. Based on a combined capability deficit and motivational model which states that 1) adolescents with suicidal behaviors and borderline features lack important interpersonal, self-regulation and distress tolerance skills, and 2) personal and environmental factors often both block and/or inhibit use of behavioral skills that adolescents do have, and at times reinforce dysfunctional behaviors. The primary adaptation for adolescents is the inclusion of family in the DBT skills training portion of therapy as well as a much greater inclusion of parents in the management of high suicide risk.
Study: NCT04811885

Intervention type: OTHER
Intervention: The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
Description: The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
Study: NCT05210335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist's recommendation to physicians about drug related problems
Description: Clinical pharmacist's recommendation to physicians about drug related problems
Study: NCT01260363

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration analgesia
Description: Local infiltration analgesia with ropivacaine 2.5mg/ml with epfinedrine 5mikrogram/ml. 20ml at harvest site and 20ml at incisionsites.
Study: NCT01702662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photopill treatment
Description: 2 courses of 5 Photopill treatments within 14 days. In each treatment, 3cm of rectal tissue will be exposed, 2 minutes per cm, to low level light therapy.